Reviews Ellence


No reviews yet.

Ellence Drug Description
Ellence®
(epirubicin hydrochloride) Injection

WARNING

Severe local tissue necrosis will occur if there is extravasation during
administration (See PRECAUTIONS). Epirubicin must not be given by the intramuscular or subcutaneous route.
Myocardial toxicity, manifested in its most severe form by potentially fatal congestive heart failure (CHF), may occur either during therapy with epirubicin
or months to years after termination of therapy. The probability of developing
clinically evident CHF is estimated as approximately 0.9% at a cumulative
dose of 550 mg/m², 1.6% at 700 mg/m², and 3.3% at 900 mg/m².
In the adjuvant treatment of breast cancer, the maximum cumulative dose used in clinical trials was 720 mg/m². The risk of developing CHF increases
rapidly with increasing total cumulative doses of epirubicin in excess of
900 mg/m²; this cumulative dose should only be exceeded with extreme
caution. Active or dormant cardiovascular disease, prior or concomitant radiotherapy
to the mediastinal/pericardial area, previous therapy with other anthracyclines
or anthracenediones, or concomitant use of other cardiotoxic drugs may increase
the risk of cardiac toxicity. Cardiac toxicity with ELLENCE may occur at lower
cumulative doses whether or not cardiac risk factors are present.
Secondary acute myelogenous leukemia (AML) has been reported in patients
with breast cancer treated with anthracyclines, including epirubicin. The
occurrence of refractory secondary leukemia is more common when such drugs
are given in combination with DNA-damaging antineoplastic agents, when patients
have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines
have been escalated. The cumulative risk of developing treatment-related AML
or myelodysplastic syndrome (MDS), in 7110 patients with breast cancer who
received adjuvant treatment with epirubicin-containing regimens, was estimated
as 0.27% at 3 years, 0.46% at 5 years and 0.55% at 8 years.
Dosage should be reduced in patients with impaired hepatic function (see
DOSAGE AND ADMINISTRATION).
Severe myelosuppression may occur.
Epirubicin should be administered only under the supervision of a physician
who is experienced in the use of cancer chemotherapeutic agents.


DRUG DESCRIPTION



What are the possible side effects of epirubicin (Ellence)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:

feeling short of breath, even with mild exertion;
swelling, rapid weight gain;
severe burning, stinging, pain, swelling, redness, or skin changes around the IV needle;
white patches or sores inside your mouth or on your lips;
...
Read All Potential Side Effects for Ellence »




ELLENCE Injection (epirubicin hydrochloride injection) is an anthracycline
cytotoxic agent, intended for intravenous administration. ELLENCE is supplied
as a sterile, clear, red solution and is available in polypropylene vials containing
50 and 200 mg of epirubicin hydrochloride as a preservative-free, ready-to-use
solution. Each milliliter of solution contains 2 mg of epirubicin hydrochloride.
Inactive ingredients include sodium chloride, USP, and water for injection,
USP. The pH of the solution has been adjusted to 3.0 with hydrochloric acid,
NF.
Epirubicin hydrochloride is the 4-epimer of doxorubicin and is a semi-synthetic
derivative of daunorubicin. The chemical name is (8S- cis)-10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
hydrochloride. The active ingredient is a red-orange hygroscopic powder, with
the empirical formula C27 H29 NO11 HCl and
a molecular weight of 579.95. The structural formula is as follows:







Last reviewed on RxList: 7/30/2008




Ellence Drug Description
Ellence®
(epirubicin hydrochloride) Injection

WARNING

Severe local tissue necrosis will occur if there is extravasation during
administration (See PRECAUTIONS). Epirubicin must not be given by the intramuscular or subcutaneous route.
Myocardial toxicity, manifested in its most severe form by potentially fatal congestive heart failure (CHF), may occur either during therapy with epirubicin
or months to years after termination of therapy. The probability of developing
clinically evident CHF is estimated as approximately 0.9% at a cumulative
dose of 550 mg/m², 1.6% at 700 mg/m², and 3.3% at 900 mg/m².
In the adjuvant treatment of breast cancer, the maximum cumulative dose used in clinical trials was 720 mg/m². The risk of developing CHF increases
rapidly with increasing total cumulative doses of epirubicin in excess of
900 mg/m²; this cumulative dose should only be exceeded with extreme
caution. Active or dormant cardiovascular disease, prior or concomitant radiotherapy
to the mediastinal/pericardial area, previous therapy with other anthracyclines
or anthracenediones, or concomitant use of other cardiotoxic drugs may increase
the risk of cardiac toxicity. Cardiac toxicity with ELLENCE may occur at lower
cumulative doses whether or not cardiac risk factors are present.
Secondary acute myelogenous leukemia (AML) has been reported in patients
with breast cancer treated with anthracyclines, including epirubicin. The
occurrence of refractory secondary leukemia is more common when such drugs
are given in combination with DNA-damaging antineoplastic agents, when patients
have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines
have been escalated. The cumulative risk of developing treatment-related AML
or myelodysplastic syndrome (MDS), in 7110 patients with breast cancer who
received adjuvant treatment with epirubicin-containing regimens, was estimated
as 0.27% at 3 years, 0.46% at 5 years and 0.55% at 8 years.
Dosage should be reduced in patients with impaired hepatic function (see
DOSAGE AND ADMINISTRATION).
Severe myelosuppression may occur.
Epirubicin should be administered only under the supervision of a physician
who is experienced in the use of cancer chemotherapeutic agents.


DRUG DESCRIPTION



What are the possible side effects of epirubicin (Ellence)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:

feeling short of breath, even with mild exertion;
swelling, rapid weight gain;
severe burning, stinging, pain, swelling, redness, or skin changes around the IV needle;
white patches or sores inside your mouth or on your lips;
...
Read All Potential Side Effects for Ellence »




ELLENCE Injection (epirubicin hydrochloride injection) is an anthracycline
cytotoxic agent, intended for intravenous administration. ELLENCE is supplied
as a sterile, clear, red solution and is available in polypropylene vials containing
50 and 200 mg of epirubicin hydrochloride as a preservative-free, ready-to-use
solution. Each milliliter of solution contains 2 mg of epirubicin hydrochloride.
Inactive ingredients include sodium chloride, USP, and water for injection,
USP. The pH of the solution has been adjusted to 3.0 with hydrochloric acid,
NF.
Epirubicin hydrochloride is the 4-epimer of doxorubicin and is a semi-synthetic
derivative of daunorubicin. The chemical name is (8S- cis)-10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
hydrochloride. The active ingredient is a red-orange hygroscopic powder, with
the empirical formula C27 H29 NO11 HCl and
a molecular weight of 579.95. The structural formula is as follows:







Last reviewed on RxList: 7/30/2008




Ellence Drug Description
Ellence®
(epirubicin hydrochloride) Injection

WARNING

Severe local tissue necrosis will occur if there is extravasation during
administration (See PRECAUTIONS). Epirubicin must not be given by the intramuscular or subcutaneous route.
Myocardial toxicity, manifested in its most severe form by potentially fatal congestive heart failure (CHF), may occur either during therapy with epirubicin
or months to years after termination of therapy. The probability of developing
clinically evident CHF is estimated as approximately 0.9% at a cumulative
dose of 550 mg/m², 1.6% at 700 mg/m², and 3.3% at 900 mg/m².
In the adjuvant treatment of breast cancer, the maximum cumulative dose used in clinical trials was 720 mg/m². The risk of developing CHF increases
rapidly with increasing total cumulative doses of epirubicin in excess of
900 mg/m²; this cumulative dose should only be exceeded with extreme
caution. Active or dormant cardiovascular disease, prior or concomitant radiotherapy
to the mediastinal/pericardial area, previous therapy with other anthracyclines
or anthracenediones, or concomitant use of other cardiotoxic drugs may increase
the risk of cardiac toxicity. Cardiac toxicity with ELLENCE may occur at lower
cumulative doses whether or not cardiac risk factors are present.
Secondary acute myelogenous leukemia (AML) has been reported in patients
with breast cancer treated with anthracyclines, including epirubicin. The
occurrence of refractory secondary leukemia is more common when such drugs
are given in combination with DNA-damaging antineoplastic agents, when patients
have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines
have been escalated. The cumulative risk of developing treatment-related AML
or myelodysplastic syndrome (MDS), in 7110 patients with breast cancer who
received adjuvant treatment with epirubicin-containing regimens, was estimated
as 0.27% at 3 years, 0.46% at 5 years and 0.55% at 8 years.
Dosage should be reduced in patients with impaired hepatic function (see
DOSAGE AND ADMINISTRATION).
Severe myelosuppression may occur.
Epirubicin should be administered only under the supervision of a physician
who is experienced in the use of cancer chemotherapeutic agents.


DRUG DESCRIPTION



What are the possible side effects of epirubicin (Ellence)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:

feeling short of breath, even with mild exertion;
swelling, rapid weight gain;
severe burning, stinging, pain, swelling, redness, or skin changes around the IV needle;
white patches or sores inside your mouth or on your lips;
...
Read All Potential Side Effects for Ellence »




ELLENCE Injection (epirubicin hydrochloride injection) is an anthracycline
cytotoxic agent, intended for intravenous administration. ELLENCE is supplied
as a sterile, clear, red solution and is available in polypropylene vials containing
50 and 200 mg of epirubicin hydrochloride as a preservative-free, ready-to-use
solution. Each milliliter of solution contains 2 mg of epirubicin hydrochloride.
Inactive ingredients include sodium chloride, USP, and water for injection,
USP. The pH of the solution has been adjusted to 3.0 with hydrochloric acid,
NF.
Epirubicin hydrochloride is the 4-epimer of doxorubicin and is a semi-synthetic
derivative of daunorubicin. The chemical name is (8S- cis)-10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
hydrochloride. The active ingredient is a red-orange hygroscopic powder, with
the empirical formula C27 H29 NO11 HCl and
a molecular weight of 579.95. The structural formula is as follows:







Last reviewed on RxList: 7/30/2008




Ellence Drug Description
Ellence®
(epirubicin hydrochloride) Injection

WARNING

Severe local tissue necrosis will occur if there is extravasation during
administration (See PRECAUTIONS). Epirubicin must not be given by the intramuscular or subcutaneous route.
Myocardial toxicity, manifested in its most severe form by potentially fatal congestive heart failure (CHF), may occur either during therapy with epirubicin
or months to years after termination of therapy. The probability of developing
clinically evident CHF is estimated as approximately 0.9% at a cumulative
dose of 550 mg/m², 1.6% at 700 mg/m², and 3.3% at 900 mg/m².
In the adjuvant treatment of breast cancer, the maximum cumulative dose used in clinical trials was 720 mg/m². The risk of developing CHF increases
rapidly with increasing total cumulative doses of epirubicin in excess of
900 mg/m²; this cumulative dose should only be exceeded with extreme
caution. Active or dormant cardiovascular disease, prior or concomitant radiotherapy
to the mediastinal/pericardial area, previous therapy with other anthracyclines
or anthracenediones, or concomitant use of other cardiotoxic drugs may increase
the risk of cardiac toxicity. Cardiac toxicity with ELLENCE may occur at lower
cumulative doses whether or not cardiac risk factors are present.
Secondary acute myelogenous leukemia (AML) has been reported in patients
with breast cancer treated with anthracyclines, including epirubicin. The
occurrence of refractory secondary leukemia is more common when such drugs
are given in combination with DNA-damaging antineoplastic agents, when patients
have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines
have been escalated. The cumulative risk of developing treatment-related AML
or myelodysplastic syndrome (MDS), in 7110 patients with breast cancer who
received adjuvant treatment with epirubicin-containing regimens, was estimated
as 0.27% at 3 years, 0.46% at 5 years and 0.55% at 8 years.
Dosage should be reduced in patients with impaired hepatic function (see
DOSAGE AND ADMINISTRATION).
Severe myelosuppression may occur.
Epirubicin should be administered only under the supervision of a physician
who is experienced in the use of cancer chemotherapeutic agents.


DRUG DESCRIPTION



What are the possible side effects of epirubicin (Ellence)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:

feeling short of breath, even with mild exertion;
swelling, rapid weight gain;
severe burning, stinging, pain, swelling, redness, or skin changes around the IV needle;
white patches or sores inside your mouth or on your lips;
...
Read All Potential Side Effects for Ellence »




ELLENCE Injection (epirubicin hydrochloride injection) is an anthracycline
cytotoxic agent, intended for intravenous administration. ELLENCE is supplied
as a sterile, clear, red solution and is available in polypropylene vials containing
50 and 200 mg of epirubicin hydrochloride as a preservative-free, ready-to-use
solution. Each milliliter of solution contains 2 mg of epirubicin hydrochloride.
Inactive ingredients include sodium chloride, USP, and water for injection,
USP. The pH of the solution has been adjusted to 3.0 with hydrochloric acid,
NF.
Epirubicin hydrochloride is the 4-epimer of doxorubicin and is a semi-synthetic
derivative of daunorubicin. The chemical name is (8S- cis)-10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
hydrochloride. The active ingredient is a red-orange hygroscopic powder, with
the empirical formula C27 H29 NO11 HCl and
a molecular weight of 579.95. The structural formula is as follows:







Last reviewed on RxList: 7/30/2008




Ellence Drug Description
Ellence®
(epirubicin hydrochloride) Injection

WARNING

Severe local tissue necrosis will occur if there is extravasation during
administration (See PRECAUTIONS). Epirubicin must not be given by the intramuscular or subcutaneous route.
Myocardial toxicity, manifested in its most severe form by potentially fatal congestive heart failure (CHF), may occur either during therapy with epirubicin
or months to years after termination of therapy. The probability of developing
clinically evident CHF is estimated as approximately 0.9% at a cumulative
dose of 550 mg/m², 1.6% at 700 mg/m², and 3.3% at 900 mg/m².
In the adjuvant treatment of breast cancer, the maximum cumulative dose used in clinical trials was 720 mg/m². The risk of developing CHF increases
rapidly with increasing total cumulative doses of epirubicin in excess of
900 mg/m²; this cumulative dose should only be exceeded with extreme
caution. Active or dormant cardiovascular disease, prior or concomitant radiotherapy
to the mediastinal/pericardial area, previous therapy with other anthracyclines
or anthracenediones, or concomitant use of other cardiotoxic drugs may increase
the risk of cardiac toxicity. Cardiac toxicity with ELLENCE may occur at lower
cumulative doses whether or not cardiac risk factors are present.
Secondary acute myelogenous leukemia (AML) has been reported in patients
with breast cancer treated with anthracyclines, including epirubicin. The
occurrence of refractory secondary leukemia is more common when such drugs
are given in combination with DNA-damaging antineoplastic agents, when patients
have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines
have been escalated. The cumulative risk of developing treatment-related AML
or myelodysplastic syndrome (MDS), in 7110 patients with breast cancer who
received adjuvant treatment with epirubicin-containing regimens, was estimated
as 0.27% at 3 years, 0.46% at 5 years and 0.55% at 8 years.
Dosage should be reduced in patients with impaired hepatic function (see
DOSAGE AND ADMINISTRATION).
Severe myelosuppression may occur.
Epirubicin should be administered only under the supervision of a physician
who is experienced in the use of cancer chemotherapeutic agents.


DRUG DESCRIPTION



What are the possible side effects of epirubicin (Ellence)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:

feeling short of breath, even with mild exertion;
swelling, rapid weight gain;
severe burning, stinging, pain, swelling, redness, or skin changes around the IV needle;
white patches or sores inside your mouth or on your lips;
...
Read All Potential Side Effects for Ellence »




ELLENCE Injection (epirubicin hydrochloride injection) is an anthracycline
cytotoxic agent, intended for intravenous administration. ELLENCE is supplied
as a sterile, clear, red solution and is available in polypropylene vials containing
50 and 200 mg of epirubicin hydrochloride as a preservative-free, ready-to-use
solution. Each milliliter of solution contains 2 mg of epirubicin hydrochloride.
Inactive ingredients include sodium chloride, USP, and water for injection,
USP. The pH of the solution has been adjusted to 3.0 with hydrochloric acid,
NF.
Epirubicin hydrochloride is the 4-epimer of doxorubicin and is a semi-synthetic
derivative of daunorubicin. The chemical name is (8S- cis)-10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
hydrochloride. The active ingredient is a red-orange hygroscopic powder, with
the empirical formula C27 H29 NO11 HCl and
a molecular weight of 579.95. The structural formula is as follows:







Last reviewed on RxList: 7/30/2008





Other reviews about Ellence on wordpress

Israel Newsletter News Roundup 8/12/2007
  by Zack Miller
Zoran (ZRAN) up strongly on Friday's upgrade by JP Morgan. Teva Pharmaceuticals (TEVA) has obtained two approvals from the US Food and Drug Administration for a generic version of […]


Delicious Dozen Stocking Stuffers
  by sarahjgim
Talk. Shop.: Because the last thing you want to have to do is *gasp!* write something down. With a pen. Like, on an actual piece of paper. The […]


Epirubicin
  by tonguelog
Epirubicin - Wikipedia, the free encyclopediaEpirubicin is an anthracycline drug used for chemotherapy. It is marketed by Pfizer under the trade name Ellence in the US and Pharmorubicin […]


Breakfast Tips
  by hturtdekan
And yes, the article goes beyond telling you that breakfast is the most important meal of the day. UPGRADE YOUR BREAKFAST There’ll always be a chunk of your day when […]


My Pledge
  by laneshaisawriter
I am my first priority, so I stand tall with my head to the sky. I am not afraid to take on a challenge, but face it on is […]


TCS,Microsoft in virtualisation deal
  by Aman Ummat
IT outsourcing firm Tata Consultancy Services has entered into an alliance with Microsoft India to launch a virtualisation Center of Exc ellence (CoE) in Chennai.The Microsoft-TCS virtualisation CoE is […]


Vacheron Constantin Collection Exce replica watche
  by rolexsreplica
Exclusive Collection Platinum is the symbol of real values - they mine 30 times less platinum than gold. And there are very few platinum mines in the world. The four […]


Aromatherapy and Cancer
  by James Geiger MD, the oilMD
Cancer and Aromatherapy. A difficult subject, complicated by lack of human studies on essential oils use during cancer treatments. So many possible statistical combinations and permutations. So many […]


UndiePants and Quickies
  by Gary G
Dear Gary, I love my husband, but he constantly wants me to wear thong underwear and show more cleavage. I don’t mind this sometimes, but it’s getting to the […]


About
  by inxellence
The inxellence group is a partnership of business advisors and strategists working with you - small and medium size enterprise (SMEs) owners and managers - to help you […]



Other reviews about Ellence on web:

Learn about the prescription medication Ellence (Epirubicin hydrochloride), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Ellence (Epirubicin hydrochloride) Drug Information: Uses, Side ...


Epirubicin is an anthracycline drug used for chemotherapy. It is marketed by Pfizer under the trade name Ellence in the US and Pharmorubicin or Epirubicin Ebewe elsewhere. Epirubicin - Wikipedia, the free encyclopedia


Ellence (epirubicin) is a cancer medication that interferes with the growth of cancer cells and is used to treat breast cancer. Includes Ellence side effects, interactions and ... Ellence Information from Drugs.com


Accurate, FDA approved Ellence information for healthcare professionals and patients - brought to you by Drugs.com. Ellence Official FDA information, side effects and uses.


Page 1 Ellence ® epirubicin hydrochloride injection WARNING 1. Severe local tissue necrosis will occur if there is extravasation during administration (See PRECAUTIONS). Ellence® epirubicin hydrochloride injection


Drug information and side-effects for Ellence ... Useful Websites. Medical Tourism Compare and save on surgery Global Translations Ellence - Drug information from MediLexicon


Find patient medical information for Ellence IV on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings. Ellence IV : Uses, Side Effects, Interactions, Pictures, Warnings ...


Official product center for ELLENCE® (epirubicin hydrochloride injection), a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following ... ELLENCE® (epirubicin hydrochloride injection): a component of ...


Articles covering Ellence: India's Dabur Pharma gets FDA approval for generic version of Pfizer's Ellence / Teva Gets FDA OK To Market Generic Ellence Injection / Teva gets ... Ellence News


Ellence is the trade name for Epirubicin. Ellence is an anti-cancer chemotherapy drug classified as an anthracyline antitumor antibiotic. Ellence, Epirubicin - Chemotherapy Drugs, Chemo Drug Side Effects





Featured Reviews

Reviews Ciclopirox Topical Solution

Penlac Drug Description Penlac® Nail Lacquer (ciclopirox) Topical Solution, 8% For use on fingernails and toenails and immediately adjacent skin only. Not for use in eyes DRUG DESCRIPTION What are the possible side effects...
Read More  |  Review This
Reviews Mitoxantrone for Injection Concentrate

Novantrone Drug Description NOVANTRONE® (mitoxantrone) for Injection Concentrate WARNING NOVANTRONE® (mitoxantrone for injection concentrate) should be administered under the supervision of a physician experienced in the...
Read More  |  Review This
Reviews Zelnorm

Zelnorm Drug Description Zelnorm® (tegaserod maleate) Tablets

DRUG DESCRIPTION What are the possible side effects of tegaserod (Zelnorm)? Get emergency medical help if you have any of these signs of an allergic reaction:...

Read More  |  Review This
Reviews Saxagliptin Tablets

Onglyza Drug Description ONGLYZA (saxagliptin) Tablets DRUG DESCRIPTION Saxagliptin is an orally-active inhibitor of the DPP4 enzyme. Saxagliptin monohydrate is described chemically as (1S,3S,5S)-2-[(2S)-2-Amino-2-(3-hydroxytricyclo[3.3.1.13,7]de...
Read More  |  Review This
Reviews Levophed

Levophed Drug Description LEVOPHED (norepinephrine bitartrate) Injection, Solution, Concentrate DRUG DESCRIPTION What are the possible side effects of norepinephrine (Levophed Bitartrate)? Get emergency medical help if you have...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....